⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838067 | 0.83 | AAK1 (0.33) | — | |
| SCHEMBL7191073 | 0.78 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL7179298 | 0.77 | L3MBTL1 (0.33) | — | |
| SCHEMBL7185923 | 0.77 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL5837322 | 0.67 | — | — | |
| SCHEMBL7194327 | 0.67 | — | — | |
| SCHEMBL5838358 | 0.67 | ALDH1A1 (0.35) | — | |
| SCHEMBL7416884 | 0.65 | ALDH1A1 (0.41) | — | |
| SCHEMBL7179304 | 0.62 | L3MBTL1 (0.37) | — | |
| SCHEMBL119711 | 0.62 | TRPV6 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004064755-A2 | METHODS FOR INHIBITING PROTEASOME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6586615-B1 | Boron compounds such as 1-amino-3,3-difluoropropyl boronate pinacol ester used as intermediates for antagonists of serine proteases, leukocyte elastases, cathepsins, chymotrypsin and hepatitis virus enzyme inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |